Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes
PURPOSE OF REVIEW: An increasing number of specialists and non-specialists are developing clinical programs to treat and cure hepatitis C virus (HCV). The goal of this paper is to evaluate and describe optimal strategies to improve outcomes related to HCV care delivery. RECENT FINDINGS: Screening an...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244618/ https://www.ncbi.nlm.nih.gov/pubmed/30524209 http://dx.doi.org/10.1007/s40506-018-0177-5 |
_version_ | 1783372086361718784 |
---|---|
author | Zuckerman, Autumn Carver, Alicia Chastain, Cody A. |
author_facet | Zuckerman, Autumn Carver, Alicia Chastain, Cody A. |
author_sort | Zuckerman, Autumn |
collection | PubMed |
description | PURPOSE OF REVIEW: An increasing number of specialists and non-specialists are developing clinical programs to treat and cure hepatitis C virus (HCV). The goal of this paper is to evaluate and describe optimal strategies to improve outcomes related to HCV care delivery. RECENT FINDINGS: Screening and diagnosis of HCV should be guided by established recommendations. Given the recognized disparity in HCV diagnosis and linkage to care, a multi-modal approach involving care coordination and technology resources should be used to improve patient engagement. Access to HCV treatment may be optimized through systematic documentation, prior authorization, and appeal processes. Treatment monitoring should emphasize medication adherence, side effect and drug interaction management, as well as elimination of practical barriers. Finally, post-treatment engagement to promote liver health and reduce the risk of complications or reinfection maximizes the benefit of HCV treatment. SUMMARY: The landscape of HCV treatment has evolved from a specialist-driven model with few patients qualifying for treatment to an opportunity for non-specialists and other providers to provide curative therapies in most patients. Innovative practice models that employ a multidisciplinary approach will likely improve screening, diagnosis, engagement, and treatment outcomes. |
format | Online Article Text |
id | pubmed-6244618 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-62446182018-12-04 Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes Zuckerman, Autumn Carver, Alicia Chastain, Cody A. Curr Treat Options Infect Dis Hepatitis C (J Raybould, Section Editor) PURPOSE OF REVIEW: An increasing number of specialists and non-specialists are developing clinical programs to treat and cure hepatitis C virus (HCV). The goal of this paper is to evaluate and describe optimal strategies to improve outcomes related to HCV care delivery. RECENT FINDINGS: Screening and diagnosis of HCV should be guided by established recommendations. Given the recognized disparity in HCV diagnosis and linkage to care, a multi-modal approach involving care coordination and technology resources should be used to improve patient engagement. Access to HCV treatment may be optimized through systematic documentation, prior authorization, and appeal processes. Treatment monitoring should emphasize medication adherence, side effect and drug interaction management, as well as elimination of practical barriers. Finally, post-treatment engagement to promote liver health and reduce the risk of complications or reinfection maximizes the benefit of HCV treatment. SUMMARY: The landscape of HCV treatment has evolved from a specialist-driven model with few patients qualifying for treatment to an opportunity for non-specialists and other providers to provide curative therapies in most patients. Innovative practice models that employ a multidisciplinary approach will likely improve screening, diagnosis, engagement, and treatment outcomes. Springer US 2018-10-18 2018 /pmc/articles/PMC6244618/ /pubmed/30524209 http://dx.doi.org/10.1007/s40506-018-0177-5 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Hepatitis C (J Raybould, Section Editor) Zuckerman, Autumn Carver, Alicia Chastain, Cody A. Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes |
title | Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes |
title_full | Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes |
title_fullStr | Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes |
title_full_unstemmed | Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes |
title_short | Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes |
title_sort | building a hepatitis c clinical program: strategies to optimize outcomes |
topic | Hepatitis C (J Raybould, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244618/ https://www.ncbi.nlm.nih.gov/pubmed/30524209 http://dx.doi.org/10.1007/s40506-018-0177-5 |
work_keys_str_mv | AT zuckermanautumn buildingahepatitiscclinicalprogramstrategiestooptimizeoutcomes AT carveralicia buildingahepatitiscclinicalprogramstrategiestooptimizeoutcomes AT chastaincodya buildingahepatitiscclinicalprogramstrategiestooptimizeoutcomes |